← FDA DRUG APPROVALS

FDA ANDA · ANDA203315

EXEMESTANE

Sponsor: RISING

APPLICATION
ANDA203315
TYPE
ANDA
ORIGINAL APPROVAL
2017-03-10
LATEST ACTION
2025-07-24
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

EXEMESTANEPrescription
EXEMESTANE 25MG · TABLET · ORAL

Approval history

2025-07-24Labeling · Supplement 6 · standardAP
2019-02-22Labeling · Supplement 2 · standardAP
2017-03-10UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →